Title

Gonadotropins: Potential Targets for Preventive and Therapeutic Interventions in Alzheimer's Disease

Document Type

Journal Article

Publisher

Future Medicine

Faculty

Computing, Health and Science

School

Exercise, Biomedical and Health Science

RAS ID

4443

Comments

This article was originally published as: Barron, A. , Verdile, G. , & Martins, R. N. (2006). Gonadotropins: potential targets for preventive and therapeutic interventions in Alzheimer's Disease. Future Neurology, 1(2), 189-202. Original article available here

Abstract

Increased prevalence of Alzheimer’s disease (AD) in women has led to an interest in the role of hormonal changes in the neurodegenerative process. In particular, research has been directed towards investigating the effect of changes in sex hormone levels following reproductive senescence. Clinical trials of hormone-replacement therapy for the prevention of AD are proving contentious, and considerably more research is necessary before the benefit of the hormone replacement strategy can be ascertained. However, evidence is now emerging to support the notion that increased gonadotropin levels may confer an increased risk of AD. Gonadotropins have been implicated in the metabolism of β-amyloid, a key protein that is central to the pathogenesis of AD. Gonadotropin reduction represents a promising new target for therapeutic intervention in AD and, potentially, dementia in general. In this review, the authors discuss the therapeutic and preventive potential of gonadotropin-reducing agents in the management of AD.

DOI

10.2217/14796708.1.2.189

 

Link to publisher version (DOI)

10.2217/14796708.1.2.189